Mantle Cell Lymphoma: From Biology to Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 25 December 2024 | Viewed by 2475

Special Issue Editor


E-Mail Website
Guest Editor
The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA
Interests: aggressive non-Hodgkin lymphomas; indolent non-Hodgkin lymphomas; Hodgkin lymphoma; Waldenstrom macroglobulinemia; targeted therapies; cellular therapies; CART
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Mantle cell lymphoma (MCL) is a heterogeneous disease comprising around 2.5–6% of B-cell non-Hodgkin lymphoma cases. The primary genetic alteration in MCL is chromosomal translocation (11;14) which leads to CyclinD1 overexpression and uncontrolled cell proliferation. There are several variants of MCL including leukemic non-nodal, classic, blastoid, and pleomorphic, which have varying biological characteristics that lead to different disease courses and long-term outcomes. There are several independent prognostic factors in MCL including the MIPI, MIPI-b, Ki-67%>30%, TP53 mutation, SOX11 expression, complex cytogenetics, and MCL35 assay with several other factors/risk scores currently under evaluation.

The survival of patients with MCL has significantly improved over the past decade due to better understanding of the disease biology and the advent of targeted therapies. Small-molecule inhibitors such as proteasome inhibitors, immunomodulators, BTK inhibitors, and BCL2 inhibitors either alone or in combination have changed the treatment landscape and outcomes regarding this disease. Several other antibody–drug conjugates, cell cycles, and intracellular signaling inhibitors are currently under evaluation. More recently, CD19-directed CART cell therapy and bispecific antibodies have ushered an era of cellular therapies in MCL with remarkable outcomes, even in high-risk subsets.

In this issue, we will focus on the advancements made in the field of MCL starting with biology and discussing the current and emerging therapies in light of these advancements.   

Dr. Narendranath Epperla
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • MCL
  • biology
  • BTK inhibitors
  • BCL2 inhibitors
  • CART
  • bispecific antibodies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 306 KiB  
Review
Targeted Therapies in the Treatment of Mantle Cell Lymphoma
by Colin J. Thomas, Veronica Carvajal and Stefan K. Barta
Cancers 2024, 16(10), 1937; https://doi.org/10.3390/cancers16101937 - 20 May 2024
Viewed by 1946
Abstract
Mantle cell lymphoma (MCL) is a rare, heterogeneous B-cell non-Hodgkin’s lymphoma. The standard front-line treatment utilizes chemotherapy, often followed by consolidation with an autologous hematopoietic cell transplant; however, in most patients, the lymphoma will recur and require subsequent treatments. Additionally, mantle cell lymphoma [...] Read more.
Mantle cell lymphoma (MCL) is a rare, heterogeneous B-cell non-Hodgkin’s lymphoma. The standard front-line treatment utilizes chemotherapy, often followed by consolidation with an autologous hematopoietic cell transplant; however, in most patients, the lymphoma will recur and require subsequent treatments. Additionally, mantle cell lymphoma primarily affects older patients and is frequently chemotherapy-resistant, which has further fostered the necessity for new, chemotherapy-free treatment options. In the past decade, targeted therapies in mantle cell lymphoma have been practice-changing as the treatment paradigm shifts further away from relying primarily on cytotoxic agents. Here, we will review the pathophysiology of mantle cell lymphoma and discuss the emergence of targeted, chemotherapy-free treatments aimed at disrupting the abnormal biology driving its lymphomagenesis. Treatments targeting the constitutive activation of NF-kB, Bruton’s Tyrosine Kinase signaling, and anti-apoptosis will be the primary focus as we discuss their clinical data and toxicities. Our review will also focus primarily on the emergence and use of targeted therapies in the relapsed/refractory setting but will also discuss the emergence of their use in front-line therapy and in combination with other agents. Full article
(This article belongs to the Special Issue Mantle Cell Lymphoma: From Biology to Therapy)
Back to TopTop